⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Supplementary Data from Acquired secondary HER2 mutations enhance HER2/MAPK signaling and promote resistance to HER2 kinase inhibition in breast cancer

Arnaldo Marín Abdullah Al Mamun Hima Patel Hiroaki Akamatsu Dan Ye Dhivya R. Sudhan Lisa D. Eli Katherine Marcelain Benjamin P. Brown Jens Meiler Carlos L. Arteaga Ariella B. Hanker

View Full Paper

Ask AI

Bookmark

Share

Abstract

Supplementary Materials and Methods, Key Resource Table, and Supplementary Figures 1-8

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Marín et al. (2024) studied this question.

synapsesocial.com/papers/68e586c1b6db6435875235fc https://doi.org/10.1158/0008-5472.27028528.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Data from Acquired secondary HER2 mutations enhance HER2/MAPK signaling and promote resistance to HER2 kinase inhibition in breast cancer2024
2Data from Acquired secondary HER2 mutations enhance HER2/MAPK signaling and promote resistance to HER2 kinase inhibition in breast cancer2024
3Supplementary Data1 from HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial2024
4Supplementary Data1 from HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial2024
5Supplementary Data 1 from Spatiotemporal Quantification of HER2-targeting Antibody–Drug Conjugate Bystander Activity and Enhancement of Solid Tumor Penetration2024